Surface immunoglobulin (Ig) on neoplastic B lymphocytes is idiotypically homogeneous for each individual tumour, both in those tumours which exhibit an obvious monoclonal plasma Ig (Wernet et al., 1972) and those which do not Hough et al., 1976) . The latter group offer a promising therapeutic target for antibody reacting with their idiotypic determinants (anti-idiotype).
Polyclonal anti-idiotype has been used to treat both animal (G.T. Haughton et al., 1978; Krolick et al., 1979) and human B-cell leukaemias, with only modest success. In contrast a case of human follicular lymphoma treated with monoclonal antiidiotype underwent dramatic regression, despite the antibody not being cytotoxic to cells in vitro (Miller et al., 1982) . It may be that the tumour described by Miller et al. exhibited physiological suppression by anti-idiotype, analogous to what has been described in normal lymphoid populations (Nisonoff & Bangasser, 1975) , whereas the other treated tumours were simply subjected to cytotoxic attack by antibody Such a dichotomy could reflect the fact that follicular lymphoma is sometimes responsive to physiological signals (Jaffe, 1982) . Alternatively the different results could reflect differences between monoclonal and polyclonal anti-idiotype, antibody dose, or other factors: the question could be resolved by further therapeutic experience. The therapeutic use of monoclonal antibodies against non-Ig lymphoma antigens (reviewed by Ritz & Schlossman, 1982) has revealed barriers similar to those encountered by polyclonal anti-idiotype in the present studies.
Here we describe further experience in treating human chronic lymphocytic leukaemia (CLL) with polyclonal anti-idiotype. Leukaemic cells, at least when in the bloodstream, are likely to be susceptible to killing by antibody and complement in a manner analogous to what can be observed in vitro, and our experience focusses attention on some of the important ways whereby the cells can elude such destruction. Patients 1. C.W., a white male aged 73, was diagnosed in May 1978 as having CLL with features characteristic of the prolymphocytic variant (Galton et al., 1974) . On presentation there was an enlarged left axillary node, splenomegaly 6cm below the costal margin, and a white cell count 92 x 1091-1 with 99% lymphocytes. Over the next 5 months the white cell count doubled and haemoglobin and platelet levels fell. From December 1978 progression was retarded by leukaphereses up to fortnightly in frequency. In October and November 1979, when the white cell count was 256 x 109I1, infusions of polyclonal anti-idiotype each appeared to remove some 10% of the total tumour load . Subsequently he was treated by chemotherapy (chlorambucil 10mg day-1 and prednisolone 20 mg day-1) and, somewhat surprisingly in view of the prolymphocytic nature of his tumour, responded well. However, the remission could not be maintained and in February 1981, having had no chemotherapy for 3 months, he was given his third course of anti-idiotype. Prior to this his white cell count was 12 x 1091-1, haemoglobin 16gdl-1, platelets IlOx 1091-1; the spleen was palpable 4cm below the coastal margin.
As described previously . The IgG1 subclass was separated from the serum with a yield of about 15 mg ml-1, as described previously . Antibody activity against the constant regions of the Fabp was removed by passing it through an immunosorbent column containing immobilized human IgM. The IgG1 was then confirmed, by indirect immunofluorescence, to contain antibody reacting with the surface Ig of the homologous CLL cells, but not with other CLL cells nor with normal lymphocytes. Immediately prior to infusion all aggregate was removed from the IgG1 by passing it through a column of Sephacryl S300 (Pharmacia) equilibrated with sterile physiological saline. The monodisperse Ig emerging from the column passed through a 0.22pm filter (Millipore), and was required to pass the limulus amoebocyte test for pyrogens (Pyrogent test, Mallinckrodt) .
Three days before each antibody infusion the patient started a course of allopurinol, 300 mg daily, to prevent hyperuricaemia. As soon as the preparation for infusion became available it was used in a cutaneous prick test for immediate hypersensitivity. Any patient who had received a previous infusion of sheep antibody also had his serum examined for precipitins to sheep IgG1, by a micro-Ouchterlony technique capable of detecting 5-10pgml-1 of antibody. Infusion was carried out slowly by the intravenous route, as described individually for each patient, with careful monitoring of pulse, respiration and temperature.
The secretion of IgG by CLL cells maintained in short-term culture was studied as described previously . Ig levels in culture supernatants and patients' sera were assessed by solid phase radioimmunoassay (Eady et al., 1975) .
In assessing the content of idiotypic Ig in patients' sera the radioimmunoassay utilized antiidiotype IgG bound to Sephadex G-25 superfine (Pharmacia) as solid phase, and idiotypic pentameric IgM as standard and radioiodinated antigen. This IgM had been prepared by sequential immunosuppression of the patient's serum: first to separate total IgM, then the idiotypic IgM . Iodination was by the lodo-gen method (Pierce Chemical Co.). The assay is sensitive to any class of serum Ig which exhibits the tumour idiotype, with the major contributions expected from IgM and IgD exported by the tumour.
Determinations of cell lysis by antibody and complement were carried out as described by F.K. Figure 1 , and are seen to be highest for CW cells. In all cases similar or slightly lower levels of killing were achieved using affinitypurified IgG antibody directed against the constant regions of the appropriate light chains.
Using human allogeneic, ABO-compatible serum as the complement source an appreciable level of killing (65-72% specific 51Cr-release) was achieved only with CW cells. Specific 5tCr-release reached only 10% for OJ, and was zero for DH and MW cells.
As reported previously ) CW serum contained idiotypic IgM, which rendered this serum a less effective source of complement than normal serum when lysis of the patient's cells. was invoked by anti-idiotype, although equally effective when lysis was invoked by anti-HLA. Figure 2 shows the effectiveness of plasmapheresis in reducing the level of inhibitory component in CW serum.
Attempts to kill DH cells by the antibodydependent cellular cytotoxicity (ADCC) mechanism, using anti-idiotype in the presence of human blood luekocytes during 18 h incubations, were unsuccessful both with and without the additional presence of fresh human serum at 25% as a source of complement.
The ability of leukaemic cells to elude complement killing by prior exposure to anti- (1.5 volumes, 1: 3 in MEM, to give a final serum concentration of 20%) was then added, the temperature was raised to 37°C, and the release of I'Cr from the cells was measured at 30 min.
idiotype at 37°C (antigenic modulation) was assessed for patients CW, MW and DH. Rabbit complement was used because of the good killing it afforded, but it should be noted that modulation against xenogenic complement can be considerably slower than against syngeneic . Full modulation (that is complete resistance to complement lysis) developed after incubations for 15-30min at 370C (Figure 3 ). Figure 4 Figure 1 . Antibody (pg ml-1) Figure 4 Antigenic modulation of DH cells as a function of antibody concentration. Cells at 105 ml1 were preincubated with antibody (IgG, ex antiidiotype serum at the indicated concentrations) for 30min at 0°C (0) or 37°C (0). The 37°C samples were then chilled, and addition of complement and subsequent processing occurred as in Figure 1 . Note that there is some escape from modulation at low concentrations of antibody when using rabbit complement. Figure 6 . It can be seen that the count reached a nadir immediately after the second infusion, but soon rebounded to exceed the pretreatment count. However at these times it was noted that the percentage of cells recoverable from Ficoll-Triosil layers had fallen appreciably, and (Figure 8 ). (14) o _ 0 1 2 3 4 5 6 Time (d) Figure 9 White cell counts (lymphocyte counts in the case of DH) recorded before and after antibody infusions in patients OJ, MW and DH. Numbers in brackets refer to times outside the range of the x-axis: days before or after therapy began. Patient OJ The patient received one course of antibody consisting of two infusions on successive days. On the first day he underwent a 41 plasma exchange, with replacement by 21 of plasma protein fraction and 21 of fresh frozen plasma. He was then given 1.3 g of antibody-containing IgG, in 510ml saline over a period of 5h. No reaction occurred. The next morning he was given a further 500ml fresh frozen plasma, and then 1.1g IgG, in 470 ml saline over 4.5 h. Again no reaction occurred.
After the two infusions the white cell count (Figure 9) Patient MW This patient also received one course of antibody consisting of two infusions on successive days. On the first day she underwent a 41 plasma exchange, with the plasma being replaced entirely by fresh frozen plasma. Antibodycontaining IgG, (1.3 g) in 500 ml saline was then infused over 5 h. The next day she was given a further 500ml of fresh frozen plasma, then 1.2g of antibody-containing IgG, in 500ml saline over 5h.
No significant fall in white cell count was observed (Figure 9) , and in all post-infusion blood samples the percentage of cells recovered after layering over Ficoll-Triosil remained high. Even after the two infusions only a small drop in the level of circulating idiotype-positive Ig was observed (Table   II) .
Cells processed from a sample taken 4 h after the first infusion were shown by indirect fluorescence microscopy to be coated with sheep antibody: about 10% stained strongly for sheep IgG, while a further 40% exhibited weak to moderate staining. The sheep antibody, and the intrinsic surface Ig examined separately, showed spottiness of fluorescence but no gross redistribution. The next day, immediately before the second infusion, the blood lymphocytes failed to stain for sheep IgG. Four hours after the second infusion the cells were again positive for sheep IgG, with 21% staining strongly and most of the remainder showing some staining. On this occasion the strongly staining cells displayed their sheep antibody in prominent caps, while extensive patching was evident on many of the more weakly staining cells. When the surface Ig was stained directly with fluoresceinated anti-K or anti-s the same capped and patched distribution was seen, but some 10% of the cells with tumour morphology failed to stain at all. Cells from a sample taken three days later had regained their original staining characteristics and showed no trace of sheep antibody.
At no time during the course of study could the harvested cells which displayed sheep antibody be lyzed simply by the addition of rabbit complement. Addition of a high concentration of anti-idiotype together with the complement gave low but consistent lysis throughout the therapy.
Patient DH This patient received only one infusion, 2.0 g of antibody-containing IgG1 in 500ml saline given over 2h. No untoward reaction occurred. Prior plasmapheresis was not considered necessary because no idiotype-positive Ig was detected in the serum.
Shortly after the infusion lymphocyte count had fallen to about 40% of the original level, but over the ensuing three days rose to regain it (Figure 9 ). Throughout this period the majority of cells were recoverable from Ficoll-Triosil gradients. Sheep IgG was detected by immunofluorescence on all tumour cells recovered immediately post-infusion, on 23% of the cells a day later, and on no cells after a further two days. In the first sample the predominant antibody distribution was circumferential and speckled, in the second most of the positive cells displayed capping. Separate staining for the cells' intrinsic surface Ig reflected these patterns. In the first sample, and only in this sample, many of the cells underwent lysis simply upon the addition of rabbit complement (using a serum selected for a high level of lytic complement). No lysis was observed in this sample upon addition of human complement.
A serum sample taken immediately post-infusion contained an appreciable concentration of free antiidiotype. Thus pre-infusion cells incubated with this serum at 0°C could subsequently be stained for sheep IgG in immunofluorescence tests, and could be lyzed upon incubation with rabbit complement at 37°C. Serum taken a day later yielded only weak staining, and failed to invoke lysis by rabbit complement. In no other patient was free antiidiotype thus demonstrable in a post-infusion serum sample.
Discussion
These early results do not reflect the therapeutic potential of anti-idiotype -being exceeded in both published (Miller et al., 1982) and current casesbut they are presented to highlight two particular problems encountered in treating neoplasms with antibody, extracellular antigen and antigenic modulation. These and other factors permitting escape of tumour cells from antibody are listed in Table III. The basic concept of therapy using anti-idiotype assumed that CLL and lymphoma cells in general synthesize Ig solely for insertion into the plasma membrane it appears now that in most of these tumours both pathways of Ig synthesis, that for membrane insertion and that for export (secretion), are active . The export of Ig per cell is small, but can yield a significant concentration of Ig in extracellular fluid when summed over a large tumour load. This has occurred in patients CW, OJ and MW. Our experience to date, exemplified by the four patients in the present study, has been that whenever export of Ig by tumour cells in vitro can be demonstrated the patient will exhibit a significant level of idiotypic Ig in his plasma. This is of some utility, as it is possible to carry out the synthetic studies well before anti-idiotype is available to assay for the presence of idiotype in plasma. The presence of extracellular antigen in the amounts encountered in the idiotype system is probably unusual among cell surface antigens in general. It is certainly not unique: Nadler et al. (1980) encountered a problem of similar magnitude in the therapeutic use of a monoclonal antibody (Ab89) reactive with about 10% of B-lymphocytic neoplasms.
An infusion of antibody in the face of circulating idiotypic Ig will result in consumption of antibody, consumption of effectors such as complement and phagocytic capacity, and possible toxic effects due to the generation of immune complexes. No serious consequence of complex formation, and in particular no significant renal damage, has been observed to follow the use of anti-idiotype or the Ab89 antibody (Nadler et al., 1980) . However the complexes probably contribute to minor immediate toxicity such as pyrexia and bronchoconstriction . These effects appear to be minimized by giving the antibody infusion slowly.
Extracellular idiotype can be reduced in amount by plasmapheresis or chemotherapeutic reduction of tumour. In the latter case sufficient time should be allowed for clearance of any Ig released from damaged cells. The need to swamp residual extracellular antigen with antibody must be taken into account in planning: it represents a strong argument in favour of monoclonal anti-idiotype (Miller et al., 1982) , which in principle at least is available in indefinitely large amount.
Appreciable killing of CW and probably of OJ cells was observed without reducing the extracellular idiotype to zero. There is a suggestion here that the effective antibody association constant might be greater for antigen on the cell surface than for antigen in the fluid phase. Uncertainties arise because there may have been transient local elimination of extracellular idiotype, and because small immune complexes might show persistent activity in assays for idiotype.
Antigenic modulation, originally defined as antibody-induced resistance to the cytotoxic action of antibody plus complement (Boyse & Old, 1969) , is associated with redistribution of antigen-antibody complexes on the cell surface (Stackpole et al., 1974) . It does not require complete clearance of the complexes from the surface, and in the case of surface Ig can occur with a rapidity sufficient to provide some protection for cells confronted simultaneously by antibody and complement . The poor performance of human complement in killing OJ, DH and MW cells in vitro was probably due largely to modulation competing with the complement cascade when antibody-coated cells were warmed to 37°C in the presence of serum. The complete modulation of CW cells at the nadir after antibody infusion suggests that it was the modulation which permitted cellular survival in vivo. The better survival afforded in a guinea pig leukaemia by univalent anti-idiotype, which avoids modulation ) is also consistent with this interpretation. It should be noted that modulation can protect against cellular effectors (Griffin et al., 1976; Stevenson et al., 1982) as well as against complement. The occurrence of modulation in human tumour cells under attack by a variety of monoclonal antibodies has recently been reviewed by Ritz & Schlossman (1982) .
Observations in this paper refer only to the killing of neoplastic cells in the vascular compartment. No diminution in size of tumour masses was observed, although the number of dead cells seen in the blood of CW soon after antibody infusion (Figure 6 ), which exceeds the total white cell count before the infusion, suggests that some cells in a readily accessible tissue compartment may have been killed and then released into the blood. Antibody-coated cells in the vascular compartment are exposed to high concentrations of complement components so it is likely that complement is here a major mechanism for cellular destruction. In contrast the usefulness of complement against cells in tissues is problematical, and some immunotherapeutic observations in animals and man suggest 'that it does not have an important role (Lanier et al., 1980; Miller et al., 1982) . Although K cells, NK cells and macrophages are known to attack antibody-coated cells in vitro (e.g. Ojo & Wigzell, 1978; Kumagai et al., 1981; Lawson & Stevenson, 1983) it is difficult to extrapolate these findings to environments in vivo. Lacking such precise knowledge makes it difficult to select antibody isotypes, and we have accordingly included in Table  III the heading inadequate or inappropriate recruitment of effectors.
Transient exhaustion of complement or cellular effectors, in the killing of cells and clearing of complexes and debris, is a possible consequence of large antibody infusions. Apparently an exhaustion of phagocytic capacity led to a delay in clearing dead cells from the blood of CW. A similar brief appearance of circulating dead cells after antibody treatment was reported by Nadler et al. (1980) . It has long been appreciated that insufficient antigen density on a target cell can lead to a failure of antibody plus complement to lyse the cell (e.g. Linscott, 1970; Lesley et al., 1974; Gordon et al., 1982) . Cell-mediated lysis (Lesley et al., 1974) or cytostasis (Lawson & Stevenson, 1983) does not appear so susceptible. Results in the present study, particularly the better complement killing observed for CW cells, are consistent with surface antigen density having a significant role in determining the susceptibility of cells to killing by antibody in the vascular compartment.
There are indications that many patients treated for tumour with antibody will eventually exhibit a troublesome immune response to the foreign Ig Ritz et al., 1981; Linch et al., 1983 ). This has not yet been observed in any of our patients, nor apparently in other patients with B-lymphocytic neoplasms. This presumably is due chiefly to the extent of diseaseassociated immunosuppression present. Other factors tending to minimize the danger of an immune response would include the meticulous removal of aggregates from the infused Ig and concomitant treatment with cytotoxic drugs.
In surveying the factors tending to limit the efficacy of antibody therapy we do not see any single item looming as completely insoluble. There appears to be no good reason why antibody therapy should not be developed as a significant and safe means of disadvantaging neoplastic cells.
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